John Leonard, PhD, on RNA-Targeting Gene Therapy for ALS, DMD
The chief scientific officer of LocanaBio discussed preclinical research presented at ASGCT 2023.
John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD
The chief scientific officer of LocanaBio discussed preclinical data with an AAV-delivered, snRN, exon 51 skipping approach presented at ASGCT 2023.